Physician profile
David Sachar
NPI 1770644478
$10,667.85
in general payments reported to CMS, 2019-2025
15 companies · $2,488 in 2025
The $2,488 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2021: $162 · 2022: $5,631 · 2023: $1,486 · 2024: $649 · 2025: $2,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219 · Honoraria: $1,600 · Consulting Fee: $705 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.00 |
| Honoraria | $1,600.00 |
| Consulting Fee | $705.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $3,055.00 | 2022-2023 | Idacio |
| Astrazeneca Pharmaceuticals LP | $2,148.00 | 2022 | |
| Abbvie INC. | $1,607.66 | 2019-2025 | Skyrizi, Rinvoq |
| Alcresta Therapeutics, INC. | $1,600.00 | 2025 | Relizorb |
| Takeda Pharmaceuticals U.S.A., INC. | $837.38 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $329.14 | 2025 | Tremfya |
| Gilead Sciences, INC. | $248.38 | 2022 | |
| Genzyme Corporation | $196.65 | 2022-2023 | |
| Boston Scientific Corporation | $193.11 | 2022-2024 | X-Tack Endoscopic Helix Tacking System, Cre Pro |
| Teleflex LLC | $180.74 | 2024 | Solesta |
| Mirum Pharmaceuticals, INC. | $126.22 | 2025 | Livmarli |
| Ironwood Pharmaceuticals, INC | $100.00 | 2019 | |
| Celltrion USA INC. | $19.46 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $13.75 | 2025 | Voquezna |
| Olympus America INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sachar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.